-
三阴性乳腺癌(triple-negative breast cancer,TNBC)是乳腺癌的一种亚型,是雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)及人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)表达均为阴性的乳腺癌。TNBC的发生率约占乳腺癌的15%,且常发生于绝经前的女性,具有预后较差、5年生存率低、侵袭性强、易复发及发生远处转移等特征[1]。目前,手术与化疗是TNBC的主要治疗方法,其中新辅助化疗的应用也越来越广泛。有研究显示,相对其他类型的乳腺癌,TNBC对新辅助化疗更敏感且更能达到病理完全缓解(pathological complete response,pCR)[2]。在目前报道的文献中,TNBC通过新辅助化疗达到的pCR率为12%~48%[3-4]。近年来,18F-FDG PET/CT在乳腺癌治疗评估中的价值已被广泛研究,其监测乳腺癌新辅助化疗疗效的价值已得到肯定[5]。本文对18F-FDG PET/CT评估TNBC的新辅助化疗疗效的研究进展进行综述。
18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展
Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy
-
摘要: 三阴性乳腺癌(TNBC)是一种雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER-2)表达均为阴性的乳腺癌亚型,常发生于绝经前的女性,具有预后较差、5年生存率低、侵袭性强、易复发及发生远处转移等特征。目前TNBC主要的治疗方法是手术与化疗,其中新辅助化疗的应用也越来越广泛。近年来,18F-FDG PET/CT在乳腺癌治疗评估中的价值已被广泛研究,PET/CT监测乳腺癌新辅助化疗疗效的价值已得到肯定。该文对18F-FDG PET/CT评估TNBC新辅助化疗疗效的研究进展进行综述。
-
关键词:
- 乳腺肿瘤 /
- 正电子发射断层显像术 /
- 体层摄影术, X线计算机 /
- 新辅助化疗
Abstract: Triple-negative breast cancer(TNBC)is a distinctive sub-group of breast cancers that do not express estrogen receptors(ER), progesterone receptors(PR) and human epidermal growth factor receptor 2(HER2). TNBC often happens to premenopausal women, and having special features such as poor prognosis, short 5-year survival, strong tumor invasion, high incidence of local recurrence and distant metastasis. Chemotherapy and surgery are mainly available systemic treatments of TNBC, and neoadjuvant chemotherapy(NAC)has become a widely used systemic treatment. Recently, the value of 18F-FDG PET/CT in breast cancer has been extensively studied, the role of PET/CT monitoring the efficacy of NAC has been a positive result. In this paper, the research progress of assessment with 18F-FDG PET/CT in TNBC during neoadjuvant chemotherapy was reviewed. -
[1] Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry[J]. Cancer, 2007, 109(9): 1721-1728. [2] Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281. [3] Bernsdorf M, Ingvar C, Jörgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase Ⅱ trial[J]. Breast Cancer Res Treat, 2011, 126(2): 463-470. [4] Iwata H, Sato N, Masuda N, et al. Docetaxel followed by fluorouracil/ epirubicin/ cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer[J]. Jpn J Clin Oncol, 2011, 41(7): 867-875. [5] Jörg Schwarz-Dose, Michael Untch, Reinhold Tiling, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with[18F]fluorodeoxyglucose[J]. J clin Oncol, 2009, 27(4): 535-541. [6] Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472): 1687-1717. [7] Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A, 2001, 98(19): 10869-10874. [8] Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10(16): 5367-5374. [9] Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers?[J]. Int J Cancer, 2008, 123(1): 236-240. [10] Nofech-Mozes S, Trudeau M, Kahn HK, et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers[J]. Breast Cancer Res Treat, 2009, 118(1): 131-137. [11] Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA, 2006, 295(21): 2492-2502. [12] de Ruijter TC, Veeck J, de Hoon JP, et al. Characteristics of triple-negative breast cancer[J]. J Cancer Res Clin Oncol, 2011, 137(2): 183-192. [13] Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer[J]. BMC Cancer, 2008, 8: 307. [14] Parikh RR, Housman D, Yang Q, et al. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 72(4): 1056-1063. [15] Samphao S, Eremin JM, El-Sheemy M, et al. Treatment of established breast cancer in post-menopausal women: role of aromatase inhibitors[J]. Surgeon, 2009, 7(1): 42-55. [16] Pienkowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease[J]. Ann Oncol, 2010, 21(5): 917-924. [17] Wang S, Yang H, Tong F, et al. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer[J]. Gan To Kagaku Ryoho, 2009, 36(2): 255-258. [18] Esserman LJ, Perou C, Cheang M, et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL(CALGB 150007/150012, ACRIN6657)[J/OL]. J Clin Oncol, 2009, 27(Suppl 18s): LBA515[2013-06-07]. http://meetinglibrary.asco.org/content/35410-65. [19] Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281. [20] Zhang C, Yan SX, Crockford S, et al. Triple-negative breast cancer is associated with higher rate of locoregional recurrence for patient achieving less than a pCR following neoadjuvant chemotherapy, surgery, and radiation therapy[J]. Inter Radiat Oncol, 2013, 87(2): S99. [21] Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors[J]. J Clin Oncol, 2006, 24(7): 1037-1044. [22] De Laurentiis M, Cianniellob D, Caputob R, et al. Treatment of triple-negative breast cancer(TNBC): current options and future perspectives[J]. Cancer Treat Rev, 2010, 36 Suppl 3: S80-86. [23] Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121: 2750-2767. [24] Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J]. Clin Cancer Res, 2013, 19(19): 5533-5540. [25] Berriolo-Riedinger A, Touzery C, Riedinger JM, et al.[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2007, 34(12): 1915-1924. [26] Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with[18F]fluorodeoxyglucose[J]. J Clin Oncol, 2009, 27(4): 535-541. [27] Groheux D, Giacchetti S, Espie' M, et al. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim[J]. Eur J Nucl Med Mol Imaging, 2011, 38(3): 419-425. [28] McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET[J]. Breast Cancer Res Treat, 2007, 102(1): 75-84. [29] Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters[J]. Cancer, 2008, 112(5): 995-1000. [30] Tchou J, Sonnad SS, Bergey MR, et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer[J]. Mol Imaging Biol, 2010, 12(6): 657-662. [31] Koolen BB, Pengel KE, Wesseling J, et al. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer[J]. Breast, 2013, 22(5): 691-697. [32] Humbert O, Berriolo-Riedinger A, Riedinger JM, et al. Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes[J]. Ann Oncol, 2012, 23(10): 2572-2577. [33] Groheux D, Hindie E, Giacchetti S, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse[J]. J Nucl Med, 2012, 53(2): 249-254. [34] Groheux D, Espié M, Giacchetti S, et al. Performance of FDG PET/CT in the clinical management of breast cancer[J]. Radiology, 2013, 266(2): 388-405. [35] Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage Ⅱ and Ⅲ breast cancer by[18F] fluorodeoxyglucose positron emission tomography[J]. J Clin Oncol, 2006, 24(34): 5366-5372. [36] Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using[18F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer[J]. J Clin Oncol, 2000, 18(8): 1689-1695.
计量
- 文章访问数: 2637
- HTML全文浏览量: 1483
- PDF下载量: 3